# Oxford BioDynamics Deliver on several important achievements & continued traction in IO

- Link: https://www.directorstalkinterviews.com/oxford-biodynamics-deliver-on-several-important-achievements-continued-traction-in-io/412800377
- Published: 2019-12-10T07:17:46+00:00
- Author: Giles Arbor

**Oxford BioDynamics Plc** (LON: OBD), a biotechnology company focused on the discovery
and development of epigenetic biomarkers based on regulatory genome architecture,
for use within the pharmaceutical and biotechnology industry, has today announced
its final results for the year ended 30 September 2019.

**Corporate and operational highlights**

 * Continued development of EpiSwitch™ biomarkers for use in immuno-oncology (IO),
   including signing of fifth commercial collaboration.
 * Participation in amyotrophic lateral sclerosis (ALS) biomarker study sponsored
   by Mitsubishi Tanabe Pharma America; first patient enrolled post period end.
 * Joined trial with Imperial College London evaluating novel methods of screening
   for prostate cancer.
 * Collaborated with Casa Sollievo della Sofferenza to develop a panel of epigenetic
   biomarkers for the diagnosis of Autistic Spectrum Disorder.
 * Study identifying epigenetic changes for monitoring disease progression in Huntington’s
   disease published in Faculty of 1000 Research.
 * Strengthened the OBD Board and team:

o Appointed Dr David Holbrook and Dr Peter Pack as Non-Executive Directors.

o Expanded into the US by forming subsidiary and appointing Glen Ferguson to lead
OBD’s business development activities in the region.

o Appointed Dr Bartu Ahiska as Senior Vice President (Commercial).

 * Awarded the prestigious Queen’s Award for Enterprise: Innovation in April 2019.
 * Expanded leading IP portfolio covering the EpiSwitch™ platform.
 * Completed expansion of UK and Malaysian R&D facilities.

**Financial highlights**

 * Revenue of £0.9m (FY18: £1.2m).
 * Operating loss of £3.7m (FY18: £2.6m).
 * Cash and term deposits of £15.5m as at 30 September 2019 (FY18: £18.3m).
 * Investment of US$540,000 into Holos Life Sciences.

**Post-period end**

 * Presentation of poster on use of EpiSwitch™ in IO, co-authored with EMD Serono,
   Pfizer and the Mayo Clinic.
 * Appointment of Professor Iain McInnes to OBD’s Scientific Advisory Board.

> **Commenting on the results, Christian Hoyer Millar, Chief Executive Officer of
> Oxford BioDynamics, said:**
> “2019 has seen OBD deliver on several important achievements. Not only have we
> signed additional collaboration agreements, but we have also seen EpiSwitch™ being
> used in high profile UK and US clinical trials. We believe there is significant
> potential for EpiSwitch™ biomarkers to benefit a range of diseases, but we have
> been particularly pleased with the progress we have announced in IO. We have continued
> to gain traction in this important, growing market demonstrating the value we 
> add to the healthcare system.
> We have invested significantly in strengthening our management team and Board,
> enhancing our presence in the US. Furthermore, the expansion of our ISO-certified
> R&D facilities in the UK and Malaysia has been completed, allowing us to further
> scale the use of our EpiSwitch™ technology.
> We are well placed to take advantage of the opportunities that this growing sector
> is offering into 2020 and beyond, and we look forward to updating the market on
> our progress.”

**Notice of Annual General Meeting**

The Company’s Annual General Meeting will be held at The Kloppenberg Room, Cohen
Quad, Exeter College, Walton Street, Oxford, OX1 2HE on 20 March 2020 at 11.00 am.

The information included in this announcement is extracted from the Annual Report,
which was approved by the Directors on 9 December 2019. Defined terms used in the
announcement refer to terms as defined in the Annual Report unless the context otherwise
requires. This announcement should be read in conjunction with, and is not a substitute
for, the full Annual Report.

The information contained within this announcement is deemed to constitute inside
information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. 
Upon the publication of this announcement, this inside information is now considered
to be in the public domain.

**CHIEF EXECUTIVE OFFICER’S REVIEW**

**Introduction**

OBD made important progress during the year ended 30 September 2019, strengthening
our commercial team and Board, receiving external validation of our EpiSwitch™ platform
from commercial partners and other collaborators, including first-time inclusion
in prospective clinical trials in the US and UK. We also completed the expansion
of our ISO-certified R&D facilities in the UK and Malaysia and the integration of
all aspects of EpiSwitch™ sample processing and analysis in-house.

In addition to our work with commercial partners, we have continued to focus on 
proprietary research in increasingly diverse high-value areas, further expanding
our intellectual property (IP) portfolio.

In April 2019, we were privileged to receive the Queen’s Award for Enterprise: Innovation.

**Commercial and scientific developments**

Validated EpiSwitch™ biomarkers have now been developed for a wide range of diagnostic
and prognostic applications, demonstrating high efficacy in stratifications in a
wide range of indications. These notably performed extremely strongly against other
conventional, invasive, biopsy-based methodologies. OBD’s technology offers commercial
partners efficient patient profiling and disease evaluation and can help clinicians
make informed decisions on preferred treatment, all based on non-invasive liquid
biopsy (a small volume blood test). The potential benefits of such actionable patient
stratifications are significant, as they help to implement precision medicine approaches
in health care (avoiding therapies likely to fail) and to de-risk drug development
for therapeutic companies (identifying the right patients for enrolment to clinical
trials).

This year OBD has provided pharmaceutical and biotechnology companies with compelling
evidence of the potential for EpiSwitch™ biomarkers to benefit IO drug development
programmes and cancer patients, by enabling clinicians to identify patients who 
are unlikely to respond to IO treatment, across a wide spectrum of indications and
treatment combinations, and helping to match potential responders to the right specific
IO drugs.

IO represents an important, growing, competitive market, with regulatory pressure
and an acknowledged need for actionable patient stratifications: some patients show
highly efficacious response to IO treatment, but many current IO therapies have 
limited utility because of low response rates and significant subsets of patients
who do not show clinically meaningful responses to treatment. OBD’s developing contribution
to the field was highlighted at the beginning of this financial year in November
2018, when the Company announced its fifth commercial collaboration in IO, with 
a major US-based biopharmaceutical company.

In May 2019, the Company presented on “EpiSwitch™ Biomarkers: Practical Applications
for Predictive, Prognostic and Diagnostic Patient Stratifications” at the China 
BIO Partnering Forum in Shanghai. The presentation focused on validated EpiSwitch
™ biomarker applications which have demonstrated high efficacy in predictive, prognostic
and diagnostic patient stratifications for lung, haematological, prostate, thyroid
and skin cancers. Specifically, the results demonstrated that the baseline predictive
stratifications by EpiSwitch™ for response to immuno-checkpoint inhibitors (a common
type of IO therapeutic) act as excellent surrogates for standard primary endpoints
used in clinical trials, such as progression free survival.

Post period end, in November 2019, OBD presented two posters co-authored with biomarker,
translational and clinical teams from EMD Serono and Pfizer, and clinical experts
from the Mayo Clinic at the Society for Immunotherapy of Cancer (SITC) annual meeting
in National Harbor, Maryland, USA. These posters provided important external validation
of the efficacy of EpiSwitch™ biomarkers in the field of IO. The OBD programme presented
at SITC focused on the development and validation of predictive biomarkers and showed
results from patients with non-small cell lung cancer (NSCLC) or melanoma who had
been treated under common IO therapeutic regimes, using avelumab (an anti-PD-L1 
antibody), pembrolizumab (an anti-PD-1 antibody), or pembrolizumab in combination
with chemotherapy, and generated models to differentiate responders from non-responders.

The results showed that IO biomarkers developed with EpiSwitch™ allowed robust exclusion
of non-responders across indications and combinations (identifying patients likely
not to respond to any IO therapy), and provided asset-specific classifiers with 
high positive predictive value (identifying likely responders to a particular drug
for a particular indication). The ability to enrich clinical trials by including
the right patients based on their genomic architecture could reduce the risk, cost
and time to market for therapeutic development programmes and could be a ‘game-changer’
in IO, enabling drug development programmes to advance with smaller patient cohorts.
There is now a compelling rationale for conducting a blinded, comparator arm test
to differentiate between the prognostic (likely overall outcome) and predictive (
likely response to a particular drug) values of the EpiSwitch™ biomarkers identified
in this work.

This year we announced OBD’s participation in the REFINE-ALS and PROSTAGRAM studies.
This is the first time the Group’s EpiSwitch™ biomarkers have been included in prospective
clinical trials, marking recognition by industry experts of the potential clinical
utility of EpiSwitch™.

· The REFINE-ALS study is led by Massachusetts General Hospital (MGH) Neurological
Clinical Research Institute (NCRI) and sponsored by Mitsubishi Tanabe Pharma America(
MTPA). It is designed to identify and measure specific biomarkers to act as a complementary
diagnostic for people being treated with RADICAVA® (edaravone) for ALS. OBD’s EpiSwitch
™ biomarkers will be assessed alongside other biomarker modalities, as well as clinical
assessments. The recruitment of the first patient (of a total of up to 300) to the
trial was announced by MTPA in October 2019.

· The aim of the PROSTAGRAM trial is to assess the role of a number of diagnostic
approaches, including magnetic resonance imaging (MRI), multiparametric ultrasound
and OBD’s EpiSwitch™ assay to screen for prostate cancer. The EpiSwitch™ assay for
prostate cancer is based on six epigenetic systemic blood-based markers and was 
developed in collaboration with Mr Mathias Winkler, Consultant Urological Surgeon
at Charing Cross Hospital, Imperial College Healthcare NHS Trust and Professor Dmitry
Pshezhetskiy, Norwich Medical School, University of East Anglia. We completed our
analysis of samples from this trial in our laboratory in the second half of the 
financial year and await overall findings, which are expected to be reported in 
early 2021.

OBD has continued to focus on carrying out proprietary research in several disease
areas. During the period the Group published results for the first prognostic biomarkers
for progression of Huntington’s disease (F1000Research, 2018, 7:175), and biomarker
stratifications with high sensitivity and predictive values for diagnosis of thyroid
cancer (Surgery, Vol 165, Issue 1, in collaboration with NorthShore University HealthSystem).
OBD was also invited to contribute a chapter to the “Handbook of Biomarkers and 
Personalized Medicine”, published in May 2019.

Since 30 September 2018, OBD has presented at a number of conferences, including
the Cantor Fitzgerald Global Healthcare Conference (New York NY), 4th Annual Biomarker
and Companion Diagnostics Conference (San Diego, CA), China BIO 2019 (Shanghai, 
China), the Nordic Life Science Days 2019 Health Tech event (Malmö, Sweden), the
Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting (National Harbor,
MD) and 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress (Kuala
Lumpur, Malaysia), where scientists from OBD’s reference laboratory in Malaysia 
presented on the successful development and validation of powerful progressive biomarkers
in type 2 diabetes mellitus (T2DM), demonstrating how OBD’s EpiSwitch™ technology
could assist experts in endocrinology in the management of T2DM and pre-diabetes.

As announced in December 2018, the Group exercised a pre-existing option to acquire,
for a nominal amount, a 30% shareholding in Holos Life Sciences Pte Ltd (“Holos”),
a company developing biomarkers to enable non-pharmaceutical enhancement of health,
wellness and performance in humans and animals. OBD also participated in Holos’ 
interim fundraising, investing US$540,000 (£422,000) in that entity. OBD and Holos
have entered into exclusive licensing agreements in both human and equine fitness,
offering the Group a combination of upfront and milestone fees and sales-based royalties.
In January 2018 the Company also announced a collaboration with Holos to develop
non-invasive epigenetic biomarkers associated with sports-related concussions suffered
by professional sportspersons, and research on this project will begin as samples
become available during the coming year.

**Strengthened team and Board**

We significantly expanded and strengthened our commercial team with the announcement
of two key appointments: Glen Ferguson, who joined in March 2019 as Senior Vice 
President (USA), to lead our business development activity in the world’s largest
healthcare market and, in June 2019, Dr Bartu Ahiska, who joined the Company as 
Senior Vice President (Commercial), to spearhead the commercialisation of the Group’s
EpiSwitch™ technology platform. Glen Ferguson’s background is in licensing and contract
negotiation, developing strategic alliances, and expertise in the field of companion
diagnostics, gained in a life sciences industry career spanning over 25 years. Dr
Bartu Ahiska is a technology entrepreneur with experience in several fields including
medical engineering, biologics, computing and graphics. Led by Glen, our business
development team has been making excellent progress with several US-based customers
and collaborators.

The OBD plc Board was joined by two new Non-Executive Directors during the year,
as Dr David Holbrook and Dr Peter Pack joined us in April 2019. Both David and Peter
have extensive life sciences sector experience and each of them has rapidly developed
a strong understanding of the Group and its business.

Also in April 2019, Stephen Diggle (founder and Chief Executive Officer of Vulpes
Investment Management, a significant investor in OBD since 2008) took on the role
of Non-Executive Chairman, on the retirement from the Board of former Non-Executive
Chairman, David Williams. Alison Kibble left her position as Non-Executive Director
in May 2019, having served the Company since 2007. We thank both David and Alison
for their commitment to OBD and wish them both every success in the future.

After the period end, in November 2019, we were pleased to announce the appointment
of Professor Iain McInnes, Professor of Experimental Medicine at Glasgow University,
to our Scientific Advisory Panel. Professor McInnes has a major interest in the 
pathogenesis of rheumatoid arthritis, psoriatic arthritis and their related co-morbidities.
He leads a translational science programme in which state-of-the-art cellular and
molecular biology techniques are applied to elucidate the mechanisms underlying 
the perpetuation of a range of chronic diseases, seeking to build precision medicine
approaches and new therapeutics thereafter.

OBD has previously collaborated with Professor McInnes and members of his group 
in the development and assessment of EpiSwitch™ biomarkers to predict the response
of patients with rheumatoid arthritis to the drug methotrexate, work which was published
in the Journal of Translational Medicine in March 2018.

**IP portfolio development**

We have continued to develop our broad IP portfolio and now have patents filed or
granted in 13 separate families, with others likely to be filed in the next few 
months. OBD’s extensive IP portfolio covers both our own platform technology and
a wide range of indication- or application-specific cases. Over the last year, we
have developed valuable IP and know-how in internal, proprietary research and development
projects as well as through work with commercial partners.

**Summary and outlook**

It has been a year of strong progress for the Company. We have entered into multiple
new research collaborations and our EpiSwitch™ platform has been used in high profile
UK and US clinical trials with world leading organisations in prostate cancer and
ALS.

We continue to gain recognition in the IO space and believe our EpiSwitch™ platform
could have a transformational impact, by reducing the clinical development risk,
cost and time to market for these important new therapeutics by enabling drug development
programmes to advance with smaller more defined patient cohorts.

We have strengthened our Board and team during the period and have continued to 
drive the development of new and significant commercial relationships in the US 
market. The expanded commercial team has already begun to see positive results in
our interactions with existing and new potential customers.

We expect to continue to expand our commercial and senior management team over the
coming months as we seek to capitalise on opportunities to commercialise the EpiSwitch
™ platform, particularly in the US.

Finally, on behalf of the Board, I would like to thank our shareholders for their
support over the last year and I look forward to reporting considerable further 
progress in 2020.

Christian Hoyer Millar

Oxford BioDynamics Chief Executive Officer

Share on:
